Rigel Pharmaceuticals Announces Board and Executive Changes
Ticker: RIGL · Form: 8-K · Filed: Mar 10, 2025 · CIK: 1034842
| Field | Detail |
|---|---|
| Company | Rigel Pharmaceuticals Inc (RIGL) |
| Form Type | 8-K |
| Filed Date | Mar 10, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, compensation, board-of-directors
TL;DR
Rigel Pharma shakes up board and exec pay. New faces, new plans.
AI Summary
Rigel Pharmaceuticals, Inc. announced on March 6, 2025, changes in its board of directors and executive compensation arrangements. The filing details the departure of certain officers and directors, the election of new directors, and updates to compensatory plans for key executives.
Why It Matters
Changes in a company's board and executive compensation can signal shifts in strategy, governance, or financial outlook, impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in leadership and compensation can indicate underlying issues or strategic realignments that may affect the company's future operations and financial health.
Key Numbers
- 0-29889 — SEC File Number (Identifies the specific SEC filing for Rigel Pharmaceuticals.)
- 94-3248524 — IRS Employer Identification No. (Tax identification number for Rigel Pharmaceuticals.)
Key Players & Entities
- Rigel Pharmaceuticals, Inc. (company) — Registrant
- March 6, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 611 Gateway Boulevard Suite 900 (address) — Principal executive offices
- South San Francisco, CA 94080 (address) — Principal executive offices location
FAQ
What specific roles have been affected by the departure of officers or directors?
The filing indicates departures of certain officers and directors but does not specify the exact roles in this summary section.
Who are the newly elected directors?
The filing mentions the election of directors but does not list their names in the provided text.
What are the key changes in the compensatory arrangements for certain officers?
The filing notes updates to compensatory arrangements but does not detail the specific changes in this section.
What is the exact date of the earliest event reported in this 8-K?
The date of the earliest event reported is March 6, 2025.
What is the principal executive office address for Rigel Pharmaceuticals?
The principal executive office is located at 611 Gateway Boulevard, Suite 900, South San Francisco, CA 94080.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 10, 2025 regarding RIGEL PHARMACEUTICALS INC (RIGL).